Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://ncbi.nlm.nih.gov/pubmed/30818873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030283
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items